Abstract
Follicular lymphoma expresses a unique immunoglobulin molecule termed idiotype that has been used as a tumor-specific antigen for vaccine development. Early stage clinical studies revealed that vaccination consisting of keyhole limpet hemocyanin-conjugated lymphoma idiotype protein in combination with granulocyte-macrophage colony-stimulating factor induced tumor-specific immune responses and molecular remission in patients with follicular lymphoma. Three double-blind, randomized, phase III trials were conducted to further determine the clinical benefits of this vaccine therapy. Compared to the placebo, prolonged disease-free survival in vaccinated patients was concluded only in one study where all the patients enrolled in the trial already had complete remission from induction chemotherapy. Next generation idiotype vaccines are being developed with the focus on simplifying vaccine formulation and potentiating tumor-specific immunity. This category includes genetically modified idiotype single chain DNA liposome-encapsulated idiotype vaccine and dendritic cell vaccine. Although preclinical data supported the immunogenicity and therapeutic advantage of these new vaccines, their clinical benefits remain to be tested. Optimizing next generation idiotype vaccines may require combination with immune adjuvants that potentiate vaccine-induced antitumor immunity, have direct effects against tumor or block immune regulatory checkpoints. Moreover, identification of a universal follicular lymphoma antigen is important for future development of vaccine therapy against this disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kwak LW, Campbell MJ, Czerwinski DK et al (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209–1215
Bendandi M, Gocke CD, Kobrin CB et al (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5:1171–1177
Schuster SJ, Neelapu SS, Gause BL et al (2011). Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 29(20):2787–2794
Neelapu SS, Kwak LW, Kobrin CB et al (2005) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11:986–991
Baskar S, Kobrin CB, Kwak LW (2004) Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest 113:1498–1510
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this paper
Cite this paper
Kwak, L.W. (2012). Translational Development of Therapeutic Vaccines for Lymphoma. In: Soh, KS., Kang, K., Harrison, D. (eds) The Primo Vascular System. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0601-3_28
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0601-3_28
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-0600-6
Online ISBN: 978-1-4614-0601-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)